Bisoprolol attenuates noradrenaline- and phenylephrine-evoked venoconstriction in man in vivo

British Journal of Clinical Pharmacology

Volumn 44, Issue 1, 1997, Pages 61-68

  Abdelmawla, A H ^a   Langley, R W ^a   Szabadi, E ^a   Bradshaw, C M ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Bisoprodol; Dorsal hand vein; Noradrenaline; Phenylephrine; 1 adrenoceptor antagonist

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BISOPROLOL FUMARATE; NORADRENALIN; PHENYLEPHRINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG MECHANISM; HEART RATE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VEIN; VEIN COMPLIANCE; VENOCONSTRICTION; VOLUNTEER;

EID: 0030789624     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00624.x     Document Type: Article

References (40)

1. Brodde O-E, Zerkowski H-R, Doetch N, Khamssi M. Subtype selective up-regulation of human saphenous vein β-adrenoceptors by chronic β-adrenoceptor antagonist treatment. Naunyn-Schmiedeberg's Arch Pharmacol 1989; 339: 479-482.
2. Vanhoutte PM, Shepherd JT. Adrenergic pharmacology of human and canine peripheral veins. Fed Proc 1985; 44: 337-340.
3. Mellander S, Anderson P-O, Afzelius L-E, Hellstrand P. Neuronal beta-adrenergic dilatation of the facial vein in man. Possible mechanism in emotional blushing. Acta Physiol Scand 1982; 114: 393-399.
4. White C de B, Udwadia BP. β-Adrenoceptors in the human dorsal hand vein, and the effects of propranolol and practolol on venous sensitivity to noradrenaline. Br J Clin Pharmacol 1975; 2: 99-105.
5. Pan HYM, Hoffman BB, Pershe RA, Blaschke TF. Decline in beta adrenergic receptor-mediated vascular relaxation with aging in man. J Pharmacol Exp Ther 1986; 239: 802-807.
6. Blöchl-Daum B, Korn A, Wolzt M, Schmidt E, Eichler H-G. In vivo studies on alpha-adrenergic subtypes in human veins. Naunyn-Schmiedeberg's Arch Pharmacol 1991; 344: 302-307.
7. Schulte KL, Laber E, Braun J, Meyer-Sabellek W, Distler A, Gotzen R. Nifedipine vasodilates human forearm arteries and dorsal hand veins constricted by specific α-adrenoceptor stimulation. Gen Pharmacol 1987; 18: 525-529.
8. Aminu JM, Vere DW. The effects of oral propranolol on the distensibility of the resting superficial veins in man. Clin Sci 1972; 42: 3P.
9. Aminu JM, Vere DW. A longitudinal study of the mechanisms of action of debrisoquine and propranolol. Br J Clin Pharmacol 1978; 6: 43-50.
10. O'Grady J, Oh V, Turner P. Effects of propranolol and oxprenolol on the venoconstrictor response to noradrenaline in the superficial hand vein in man. Eur J Clin Pharmacol 1978; 14: 83-85.
11. Bowman AJ, Chen CPL-H, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994; 39: 199-204.
12. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-1071.
13. 1-adrenoceptor antagonist: in vitro and in vivo studies. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S29-S35.
14. 3H]-carazolol binding to β-adrenoceptors. Application to study of β-adrenergic receptor subtypes in canine ventricular myocardium and lung. Circ Res 1981; 49: 326-336.
15. Aellig WH. A new technique for recording compliance of human hand veins. Br J Clin Pharmacol 1981; 11: 237-243.
16. Abdelmawla AH, Langley RW, Szabadi E, Bradshaw CM. Bisoprolol attenuates noradrenaline- and phenylephrine-evoked venoconstriction in man in vivo. Br J Clin Pharmacol 1996; 41: 443p.
17. Abdelmawla AH, Langley RW, Szabadi E, Bradshaw CM. Comparison of the effects of desipramine on noradrenaline- and methoxamine-evoked venoconstriction in man in vivo. Br J Clin Pharmacol 1995; 40: 445-451.
18. Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmaeol 1986; 8(suppl. 11): S16-S20.
19. Le Coz F, Sauleman P, Poirier JM, et al. Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers. J Cardiovasc Pharmacol 1991; 18: 28-34.
20. Wilkinson GN. Statistical estimations in enzyme kinetics. Biochem J 1961; 80: 324-332.
21. Lewis D. Quantitative methods in psychology. Springer, New York, Berlin, Heidelberg, 1960.
22. Glusa E, Markwardt F. Characterisation of postjunctional α-adrenoceptors in isolated human femoral veins and arteries. Naunyn-Schmiedeberg's Arch Pharmacol 1983; 323: 101-105.
23. Richards DA, Tuckman J, Prichard BNC. Assessment of α- and β-adrenoceptor blocking actions of labetalol. Br J Clin Pharmacol 1976; 3: 849-855.
24. Thulesius O, Gjöres JE, Berlin E. α- and β-adrenoceptor blockade by labetalol in human isolated arteries and veins. Br J Clin Pharmacol 1980; 9: 621-622.
25. Belz GG, Beermann C, Schloos J, Neugebauer G. Influence of carvedilol on the responsiveness of the human hand veins to noradrenaline and dinoprost. Drugs 1988; 36 (Suppl. 6): 69-74.
26. Beermann C, Schloos J, Belz GG. Constriction of the human dorsal hand veins in vivo with several vasoconstrictors and the influence of oral administration of carvedilol. J Cardiovasc Pharmacol 1992; 19 (Suppl. 1): S12-S17.
27. 2α- and noradrenaline-induced contraction of the human hand veins in vivo. Clin Invest 1992; 70: S13-S19.
28. Ariëns EJ, Simonis AM, van Rossum JM. Drug-receptor interaction: interaction of one or more drugs with different receptor systems. In Molecular pharmacology, ed Ariëns EJ, New York: Academic Press, 1964: 287-393.
29. Van den Brink FG. The model of functional interaction. I. Development and first check of a new model of functional synergism and antagonism. Eur J Pharmacol 1973; 22: 270-278.
30. Collier JG, Pitcher DW. Effect of SK&F 92657 on the superficial hand veins and forearm arterioles of man. Br J Clin Pharmacol 1980; 93: 301P.
31. 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S2-S15.
32. 1-selective adrenoceptor antagonist bisoprolol. J Cardiovasc Pharmacol 1994; 23: 897-906.
33. Collier JG, Lorge RE, Robinson BF. Comparison of the effects of tolmesoxide (RX71107), diazoxide, hydrallazine, prazosin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand vein in man. Br J Clin Pharmacol 1978; 5: 35-44.
34. Webb DJ, Benjamin N, Vallance P. The potassium channel opening drug cromakalin produces arterioselective vasodilation in the upper limbs of normal volunteers. Br J Clin Pharmacol 1989; 27: 757-761.
35. Lammers JWJ, Folgering HthM, van Herwaarden CLA. Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S69-S73.
36. Chatterjee SS. The cardioselective and hypotensive effects of bisoprolol in hypotensive asthmatics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S74-S77.
37. Burkart F, Pfisterer M, Steinmann E. Effects of bisoprolol in relation to metoprolol and bufuralol on left ventricular haemodynamics at rest and during exercise in chronic ischaemic heart disease. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S78-S82.
38. Eichler H-G, Blöchl-Daum B, Eichler I, Wolzt M, Korn A, Götz M. Normal responsiveness of superficial hand veins to alpha- and beta-adrenergic stimuli in allergic asthma: effects of terbutaline and prednisolone on beta-adrenergic responsiveness. J Allergy Clin Immunol 1990; 86: 714-725.
39. Stein M, Deegan R, Wood AJJ. Long-term exposure to β2-receptor agonist specifically desensitizes β-receptor-mediated venodilatation. Clin Pharmacol Ther 1993; 54: 187-193.
40. Szabadi E. A model of functionally antagonistic receptor populations activated by the same agonist. J Theor Biol 1977; 69: 101-112.